A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
Clinical trial NCT01896479 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT01896479
- Sponsor
- Exelixis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2015-02-25
- Primary completion
- 2020-07-15
- Enrollment
- 247
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.